These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30146959)

  • 21. Novel Programs and Discoveries Aim to Combat Antibiotic Resistance.
    Hampton T
    JAMA; 2015 Jun 23-30; 313(24):2411-3. PubMed ID: 26039283
    [No Abstract]   [Full Text] [Related]  

  • 22. The global challenge of new classes of antibacterial agents: an industry perspective.
    Fernandes P
    Curr Opin Pharmacol; 2015 Oct; 24():7-11. PubMed ID: 26119487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simulating Market Entry Rewards for Antibiotics Development.
    Okhravi C; Callegari S; McKeever S; Kronlid C; Baraldi E; Lindahl O; Ciabuschi F
    J Law Med Ethics; 2018 Jun; 46(1_suppl):32-42. PubMed ID: 30146961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic Pipeline Coordinators.
    Baraldi E; Lindahl O; Savic M; Findlay D; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):25-31. PubMed ID: 30146958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

  • 26. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E; Ciabuschi F; Leach R; Morel CM; Waluszewski A
    Am J Law Med; 2016 May; 42(2-3):451-486. PubMed ID: 29086643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH; Outterson K
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of funding could undermine UK antibiotic resistance strategy, say experts.
    O'Dowd A
    BMJ; 2013 Dec; 347():f7618. PubMed ID: 24355390
    [No Abstract]   [Full Text] [Related]  

  • 30. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B; Sharma P; Rex JH
    Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
    [No Abstract]   [Full Text] [Related]  

  • 31. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 32. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming the current deadlock in antibiotic research.
    Schäberle TF; Hack IM
    Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibiotics in late clinical development.
    Fernandes P; Martens E
    Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulating antibiotic development.
    Tillotson G
    Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
    [No Abstract]   [Full Text] [Related]  

  • 39. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award.
    Daniel GW; Schneider M; McClellan MB
    JAMA; 2017 Sep; 318(12):1103-1104. PubMed ID: 28772301
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.